文献速递糖尿病

妊娠期2型糖尿病女性孕期使用二甲双胍与围产期结局的关联

Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus.
PubMed 文献 · Diabetes Care · 2024-01-01

该研究利用美国两个医疗索赔数据库(2000-2020年)模拟改良随机试验,比较孕前使用二甲双胍联合胰岛素的2型糖尿病女性在孕期继续与停用二甲双胍的围产期结局。共纳入2983例,72%停用二甲双胍;复合结局风险继续组46% vs 停用组48%,调整RR 0.92(95%CI 0.81,1.03)。结论与MiTy试验一致,继续使用二甲双胍未增加新生儿复合不良结局风险,但可能与小于胎龄儿风险相关,需进一步考虑。

要点

  • 孕前使用二甲双胍联合胰岛素的2型糖尿病女性中,72%在孕期停用二甲双胍。
  • 继续组复合结局风险46% vs 停用组48%,调整RR 0.92(95%CI 0.81,1.03)。
  • 小于胎龄儿风险仅在商业保险人群中继续组升高,需进一步考虑。

核心结论

  • 研究结果与MiTy随机试验一致,孕期继续使用二甲双胍未增加新生儿复合不良结局风险。
  • 但二甲双胍可能与小于胎龄儿风险相关,需进一步考虑。

研究设计与样本

  • 利用美国两个医疗索赔数据库(2000-2020年)模拟改良随机试验(MiTy)。
  • 纳入孕前使用二甲双胍联合胰岛素治疗的18-45岁2型糖尿病孕妇,共2983例。
  • 比较孕期继续与停用二甲双胍的围产期结局,并调整人口学特征、合并症及糖尿病进展替代指标等基线混杂因素。

主要发现

  • 2983例中72%在孕期停用二甲双胍,继续组平均受孕年龄32岁,多种合并症患病率更高。
  • 复合结局(早产、产伤、新生儿呼吸窘迫、新生儿低血糖、新生儿重症监护室入住)风险继续组46% vs 停用组48%,调整RR 0.92(95%CI 0.81,1.03)。
  • 大多数次要结局在两种治疗间相似且两个数据库一致,但小于胎龄儿仅在商业保险人群中继续组升高。

局限性

  • 小于胎龄儿风险仅在商业保险人群中继续组升高,二甲双胍相关风险需进一步考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We emulated a modified randomized trial (Metformin in Women With Type 2 Diabetes in Pregnancy [MiTy]) to compare the perinatal outcomes in women continuing versus discontinuing metformin during pregnancy among those with type 2 diabetes treated with metformin plus insulin before pregnancy. RESEARCH DESIGN AND METHODS: This study used two health care claims databases (U.S., 2000-2020). Pregnant women age 18-45 years with type 2 diabetes who were treated with metformin plus insulin at conception were eligible. The primary outcome was a composite of preterm birth, birth injury, neonatal respiratory distress, neonatal hypoglycemia, and neonatal intensive care unit admission. Secondary outcomes included the components of the primary composite outcome, gestational hypertension, preeclampsia, maternal hypoglycemia, cesarean delivery, infants large for gestational age, infants small for gestational age (SGA), sepsis, and hyperbilirubinemia. We adjusted for potential baseline confounders, including demographic characteristics, comorbidities, and proxies for diabetes progression. RESULTS: Of 2,983 eligible patients, 72% discontinued use of metformin during pregnancy. The average age at conception was 32 years, and the prevalence of several comorbidities was higher among continuers. The risk of the composite outcome was 46% for continuers and 48% for discontinuers. The adjusted risk ratio was 0.92 (95% CI 0.81, 1.03). Risks were similar between treatments and consistent between databases for most secondary outcomes, except for SGA, which was elevated in continuers only in the commercially insured population. CONCLUSIONS: Our findings were consistent with those reported in the MiTy randomized trial. Continuing metformin during pregnancy was not associated with increased risk of a neonatal composite adverse outcome. However, a possible metformin-associated risk of SGA warrants further consideration.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yland JJ, Huybrechts KF, Wesselink AK, et al. Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes Care. 2024. PMID: 39042587. doi:10.2337/dc23-2056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。